FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to pharmaceutical industry, namely to a preparation for treating an inflammatory condition related to ischemia. A pharmaceutical preparation for treating the internal inflammatory condition related to ischemia containing: a) normal saline containing at least 105 peripheral mononuclear cells (PMC) or their population per one ml, or b) supernatant of normal saline a), wherein normal saline a) is prepared by culturing the PMC or their population in normal saline free from PMC-proliferating or PMC-activating substances; the PMC or their population is cultured in the environment causing the pre- or intra-culture stress. Using the preparation for producing a therapeutic agent for treating the internal inflammatory condition related to ischemia. A method for preparing the pharmaceutical preparation.
EFFECT: pharmaceutical preparation possesses higher clinical effectiveness in the internal inflammatory processes related to ischemia.
13 cl, 20 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PREPARATION CONTAINING SUPERNATANT OF BLOOD MONONUCLEAR CELL CULTURE | 2009 |
|
RU2533253C2 |
| COMPOSITION FOR TREATING OR PREVENTING ALLERGY OR ALLERGIC REACTION | 2020 |
|
RU2827897C1 |
| SECRETOME ACTIVITY ANALYSIS | 2018 |
|
RU2790567C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| PROSTAGLANDIN/CYCLOOXYGENASE PATHWAY MODULATION | 2007 |
|
RU2448712C2 |
| CHAPERONIN 10 MODULATION OF TOLL-LIKE RECEPTOR INDUCIBLE CYTOKINE AND CHEMOKINE SECRETION | 2005 |
|
RU2446817C2 |
| METHOD FOR PRECLINICAL TESTING OF IMMUNOMODULATORY AGENTS | 2010 |
|
RU2519641C2 |
| MYOCARDIAL INFARCTION TREATMENT USING TGF-BETA ANTAGONISTS | 2011 |
|
RU2637088C2 |
| 5-(4-METHANESULPHONYL PHENYL)THIAZOLE DERIVATIVES FOR TREATING ACUTE AND CHRONIC INFLAMMATORY DISEASES | 2009 |
|
RU2495031C2 |
| LINEAR OR CYCLIC PEPTIDES, THEIR USING AND METHOD OF PATIENT TREATMENT | 1993 |
|
RU2130317C1 |
